PMID: 19925729Nov 21, 2009Paper

Treatment of wet age-related macular degeneration with vascular endothelial growth factor. A survey of a Cochrane review

Ugeskrift for laeger
Sara Brandi Bloch, Michael Larsen

Abstract

This evaluation of a Cochrane-review including five clinical trials of good methodological quality indicates that the antiangiogenic therapeutic agents, pegaptanib and ranibizumab, are effective treatment strategies for neovascular Age-Related Macular Degeneration (AMD). The review does not include a direct comparison or an indirect statistical comparison between the two antiangiogenic agents. In clinical practice ranibizumab compared to pegaptanib is the drug of choice because of cost-utility analysis and the number of patients gaining visual acuity.

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.